Ronald Christopher Chatelier

Dr. Ronald Christopher Chatelier

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AMAshwin K. V. Mruthunjaya
Ashwin K. V. Mruthunjaya
RCRonald Christopher Chatelier
Ronald Christopher Chatelier
Angel A. J. TorrieroAngel A. J. Torriero
Angel A. J. Torriero
Dabigatran etexilate, an oral prodrug, is often used to treat complications linked to thrombosis. Dabigatran (DAB, active form) does not need to be monitored. However, there are several conditions, such as reduced renal function, traumatic bleeding, emergency surgery, the need for thrombolytic therapy in acute stroke, or the requirement to use other forms of anticoagulation, where knowing the concentration of DAB in the blood is indispensable. Unfortunately, there are no convenient DAB-specific point-of-care tests available. To solve this problem, two disposable sensors were constructed and optimised in this work to detect the anticoagulant drug DAB using novel co-facing disposable electrodes, which allows a calibration-free quantitation of the electroactive mediator concentration. A trypsin-based sensor was evaluated. This sensor performed well in a 10 mM Tris buffer (pH 8.8) solution. However, trypsin was inhibited by alpha-1 antitrypsin when a plasma sample was introduced into the sensor. This problem was overcome by plasma filtration. This sensor showed a detection limit of 50.7 ng mL−1 DAB in plasma and a quantification range of 177–500 ng mL−1. A thrombin-based sensor was also constructed. This sensor performed well in ten-fold diluted plasma, overcoming the filtration problem observed with the trypsin-based sensor. This sensor showed a detection limit of 9.6 ng mL−1 DAB in plasma and a quantification range of 11.5–140 ng mL−1. Its extensive pH stability range, the possibility of working at physiological pH, low volume, low cost, and fast turnaround response (less than 20 s) make the calibration-free thrombin-based sensor a suitable point-of-care test to measure DAB concentration in the blood.

17 May 2023 in Electrochimica Acta
Verified
Journal Article
Open access
AMAshwin Kumar Varamballi Mruthunjaya
Ashwin Kumar Varamballi Mruthunjaya
AHAlastair M. Hodges
Alastair M. Hodges
RCRonald Christopher Chatelier
Ronald Christopher Chatelier
Angel A. J. TorrieroAngel A. J. Torriero
Angel A. J. Torriero

1 May 1997 in Langmuir
Verified
Journal Article
Closed access
RCRonald Christopher Chatelier
Ronald Christopher Chatelier
AHAlastair M. Hodges
Alastair M. Hodges
CDCalum John Drummond
Calum John Drummond
DCDerek Y. C. Chan
Derek Y. C. Chan
HGHans Griesser
Hans Griesser

25 December 2023 in Talanta
Verified
Journal Article
Open access
AMAshwin Kumar Varamballi Mruthunjaya
Ashwin Kumar Varamballi Mruthunjaya
RCRonald Christopher Chatelier
Ronald Christopher Chatelier
Angel A. J. TorrieroAngel A. J. Torriero
Angel A. J. Torriero
This article presents a novel proof of concept for the blood plasma quantification of clinically relevant concentrations of direct oral anticoagulants, DOACs, including rivaroxaban and edoxaban, as well as low-molecular-weight heparins, LMWHs, such as enoxaparin and dalteparin, utilising a calibration-free disposable electrochemical sensor with co-facing electrodes. A dose-response curve was generated for rivaroxaban and edoxaban to demonstrate the sensor's ability to detect ≥9.00 ng mL-1 rivaroxaban and quantify it in the 11.0-140 ng mL-1 range. Similarly, the lower detection limit for edoxaban was 12.9 ng mL-1, with a quantification range of 16.8-140 ng mL-1. The significance of this sensor lies in its ability to quantify rivaroxaban and edoxaban below 30 ng mL-1, which is crucial in emergency care centres when patients undergoing DOAC therapy require emergency surgery or reversal of DOACs due to bleeding or ischemic stroke. Furthermore, the sensor can detect ≥0.016 IU mL-1 enoxaparin and ≥0.013 IU mL-1 dalteparin and quantify them in the 0.025-0.75 and 0.019-0.75 IU mL-1 range, respectively. Additionally, a dose-response curve was presented to demonstrate the potential ability of this sensor to quantify factor-Xa inhibitors independently of which DOACs or LMWHs are used. With the assay completed in less than 30 s using a minimal volume of 7 μL sample, the possibility to work at physiological pH and under calibration-free format makes this assay an excellent candidate for point-of-care testing.